Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to -$6.7 million.

  • Haemonetics' Change in Accured Expenses fell 30235.72% to -$6.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$19.3 million, marking a year-over-year decrease of 25175.48%. This contributed to the annual value of -$19.2 million for FY2025, which is 14308.47% down from last year.
  • Haemonetics' Change in Accured Expenses amounted to -$6.7 million in Q4 2025, which was down 30235.72% from $17.7 million recorded in Q3 2025.
  • Haemonetics' Change in Accured Expenses' 5-year high stood at $49.5 million during Q1 2024, with a 5-year trough of -$47.9 million in Q2 2025.
  • In the last 5 years, Haemonetics' Change in Accured Expenses had a median value of $3.9 million in 2021 and averaged $51750.0.
  • Per our database at Business Quant, Haemonetics' Change in Accured Expenses crashed by 1247730.5% in 2021 and then surged by 83631.17% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' Change in Accured Expenses stood at $3.8 million in 2021, then soared by 89.79% to $7.3 million in 2022, then plummeted by 424.4% to -$23.7 million in 2023, then surged by 113.96% to $3.3 million in 2024, then crashed by 302.36% to -$6.7 million in 2025.
  • Its last three reported values are -$6.7 million in Q4 2025, $17.7 million for Q3 2025, and -$47.9 million during Q2 2025.